Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Alec Pencz"'
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 2, Pp 1189-1193 (2021)
This case discusses a 62-year-old woman with de novo metastatic lung adenocarcinoma (PD-L1 >50% with a KRAS G12C mutation, ALK and EGFR negative) who was on pembrolizumab for 1 year without any significant toxicity, only low-grade dermatitis and hypo
Externí odkaz:
https://doaj.org/article/b49e0bb04f7a4f9698e99c787f282971
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 2, Pp 1189-1193 (2021)
Case Reports in Oncology
Case Reports in Oncology
This case discusses a 62-year-old woman with de novo metastatic lung adenocarcinoma (PD-L1 >50% with a KRAS G12C mutation, ALK and EGFR negative) who was on pembrolizumab for 1 year without any significant toxicity, only low-grade dermatitis and hypo
Autor:
M. Sara Kuruvilla, Geoffrey Liu, Iqra Syed, Femida Gwadry-Sridhar, Brandon S. Sheffield, Robin Sachdeva, Alec Pencz, Luna Zhan, Katrina Hueniken, Devalben Patel, Karmugi Balaratnam, Khaleeq Khan, Benjamin Grant, Shawna Noy, Karan Singh, Linda Liu, Muhammad Rakibuz-Zaman, Daniel Moldaver, Mary Kate Shanahan, Parneet K. Cheema
Publikováno v:
SSRN Electronic Journal.
The ADAURA trial demonstrated the benefit of adjuvant osimertinib among patients with resected, early-stage, epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). To understand the potential population impact, it is cri